DIADIA0.87%
SPYSPY0.60%
QQQQQQ0.49%
Trending
Top trending tickerAEROAERO17.67%
WFFWFF499.51%
GRRRGRRR6.78%
TAOTAO3.54%
ARBARB5.02%
UBERUBER1.81%
KTAKTA0.48%
RYCEYRYCEY0.66%
VLOVLO2.27%
MPCMPC1.79%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolVNDAnews
Exchange: NASDAQ·Updated 07:54 PM EDT

VNDA News

News
all
press releases
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual MeetingPR NewswireWASHINGTON, Oct. 2, 2026WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the...
PR Newswire
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual MeetingPR NewswireWASHINGTON, Oct. 2, 2026WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the...
PR Newswire
More News
VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD).
Stocktwits
Why Are Nasdaq Futures Rising Premarket? MU, TSLA, CAPR, VNDA, ASTS, HOOD, BA Stocks In Focus
On Stocktwits, retail sentiment toward SPY and QQQ stayed ‘bullish.’
Stocktwits
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
Stocktwits
Vanda's HETLIOZ Meets Phase 3 Goal In Delayed Sleep-Wake Phase Disorder; Stock Up
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) reported positive topline results from a Phase 3 study of HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD...
Nasdaq News: Markets
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase DisorderPR NewswireWASHINGTON, Sept. 29, 2026Study met its primary...
PR Newswire
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences PR Newswire WASHINGTON, Sept. 2, 2026 WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA...
PR Newswire
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission PR Newswire...
PR Newswire
NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. PR Newswire WASHINGTON, Aug. 22, 2026 WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc...
PR Newswire
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Zacks

Advertisement|Remove ads.